RegenLab USA, Inc. (RGNA)
| Market Cap | 157.24M |
| Revenue (ttm) | 54.26M |
| Net Income | -1.14M |
| EPS | -0.05 |
| Shares Out | 22.46M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About RGNA
RegenLab is a science-driven regenerative medicine company originally founded in Switzerland and now structured under RegenLab USA, our U.S.-based holding entity. We operate through a fully integrated platform with three manufacturing sites and dedicated R&D and clinical teams based in New Jersey (USA), Paris (France), and Monthey (Switzerland). Across these sites, we maintain full control of the development and industrialization cycle, including GMP manufacturing, clinical and regulatory affairs, and global IP management. RegenLab is the holde... [Read more]
Financial Performance
Financial StatementsNews
Regenerative medicine device provider RegenLab USA files for a $35 million IPO
RegenLab USA, which provides medical devices for tissue repair and other regenerative medicinal uses, filed on Friday with the SEC to raise up to $35 million in an initial public offering.
RegenLab USA IPO Registration Document (S-1)
RegenLab USA has filed to go public with an IPO on the NASDAQ